Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion

Abstract

This pilot study suggests that the degree of B cell depletion, rather than the dose of rituximab, determines clinical response. It may be possible to predict which patients will respond to lower-dose rituximab, and this may allow more cost-effective treatment.